UNSPSC 51422213: Triamcinolone acetonide valerate

This classification denotes a therapeutic glucocorticoid with the molecular formula C29H39FO7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier H6942ZVG0C, chemically known as pregna-1,4-diene-3,20-dione, 9-fluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-21-((1-oxopentyl)oxy)-, (11.beta.,16.alpha.)-, but more generally known as triamcinolone acetonide valerate, which bears US NIH Compound Identifier 60904.

European Medicines Agency schedules triamcinolone acetonide valerate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11251MIG. Most nations, for tariff purposes, schedule triamcinolone acetonide valerate under HS 29372200. SMILES: CCCCC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3CCC5=CC(=O)C=C[C@@]54C)F)O)C)OC(O2)(C)C.

UNSPSC 51422213 Triamcinolone acetonide valerate is a Commodity code that in recent state and local practice encompasses procurement of pharmaceutical products and related health-system supplies, though the posted opportunities under this code show significant mismatch with the nominal product scope. State and local health departments, county health systems, and state health agencies solicit under this code for items ranging from prescription medications to naloxone and drug deactivation systems used in community health and public safety initiatives. The issuing bodies include county-level public health departments and state health and human services commissions managing pharmacy benefits and emergency response programs.

Recent activity appears limited and geographically concentrated. Seminole County, Florida posted an IFB (No. IFB60459723LAS) on June 30, 2026, for procurement of 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, for quarterly delivery to the Seminole County Community Health Building; the contract carries a two-year initial term with optional one-year renewal and includes workers' compensation, commercial general liability, and professional liability insurance requirements. The Texas Health and Human Services Commission issued RFI No. HHS0017013 on April 3, 2026, seeking vendor capability information on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling preliminary market research rather than immediate procurement intent. The code shows sparse recent activity and the opportunities posted do not align cleanly with triamcinolone acetonide valerate as a specific pharmaceutical product line — vendors pursuing this code should verify alignment with actual commodity scope before preparing responses.